These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2935075)

  • 21. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions of [14C]phosphonoformic acid with renal cortical brush-border membranes. Relationship to the Na+-phosphate co-transporter.
    Szczepanska-Konkel M; Yusufi AN; Dousa TP
    J Biol Chem; 1987 Jun; 262(17):8000-10. PubMed ID: 2954950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
    Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The action of epidermal growth factor (EGF) is limited to specific phases of the cell cycle in an EGF dependent colonic cell line.
    Sizeland A; Bol S; Burgess AW
    Growth Factors; 1991; 4(2):129-43. PubMed ID: 2049180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoids increase the length of the G2 and M phases of the HeLa S3 cell cycle.
    Fanger BO; Schreifer J; Cidlowski JA
    J Steroid Biochem; 1987 Sep; 28(3):345-7. PubMed ID: 3657157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mode of action of phosphonoformate as an anti-herpes simplex virus agent.
    Cheng YC; Grill S; Derse D; Chen JY; Caradonna SJ; Connor K
    Biochim Biophys Acta; 1981 Jan; 652(1):90-8. PubMed ID: 6260189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of action of foscarnet against viral polymerases.
    Crumpacker CS
    Am J Med; 1992 Feb; 92(2A):3S-7S. PubMed ID: 1371038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?
    Hansson BG; Riesbeck K; Nordenfelt E; Weiland O
    Prog Clin Biol Res; 1991; 364():421-7. PubMed ID: 1826956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Foscarnet.
    Lancet; 1985 Sep; 2(8456):648-9. PubMed ID: 2863637
    [No Abstract]   [Full Text] [Related]  

  • 30. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells.
    MacLeod CL; Luk A; Castagnola J; Cronin M; Mendelsohn J
    J Cell Physiol; 1986 Apr; 127(1):175-82. PubMed ID: 3007537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foscarnet for cytomegalovirus infections.
    Ringdén O; Wilczek H; Lönnqvist B; Gahrton G; Wahren B; Lernestedt JO
    Lancet; 1985 Jun; 1(8444):1503-4. PubMed ID: 2861426
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
    Al-Samarai A; Kinghorn G; Potter C
    Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of HTLV-III/LAV replication by foscarnet.
    Sarin PS; Taguchi Y; Sun D; Thornton A; Gallo RC; Oberg B
    Biochem Pharmacol; 1985 Nov; 34(22):4075-9. PubMed ID: 2415134
    [No Abstract]   [Full Text] [Related]  

  • 36. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro inhibition of human herpesvirus-6 by phosphonoformate.
    Streicher HZ; Hung CL; Ablashi DV; Hellman K; Saxinger C; Fullen J; Salahuddin SZ
    J Virol Methods; 1988 Sep; 21(1-4):301-4. PubMed ID: 2972736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
    Pettersson KJ; Nordgren T; Westerlund D
    J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foscarnet in fulminant hepatitis B.
    Price JS; France AJ; Moaven LD; Welsby PD
    Lancet; 1986 Nov; 2(8518):1273. PubMed ID: 2878146
    [No Abstract]   [Full Text] [Related]  

  • 40. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
    Sullivan V; Coen DM
    J Infect Dis; 1991 Oct; 164(4):781-4. PubMed ID: 1654362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.